InMed Pharmaceuticals, Inc. (IMLFF)

Our latest clients all have the potential to grow significantly in the near and long-term future

Re: InMed Pharmaceuticals, Inc. (IMLFF)

Postby QualityStocks » Fri Aug 18, 2017 3:35 pm

NetworkNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Enters Consulting Agreement with Creative Capital Media

Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced its entry into a consulting agreement with Creative Capital Media (“CCM”). Moving forward, CCM, a media and advertising consultancy, will provide communication and awareness services to InMed in North America.
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 613
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: InMed Pharmaceuticals, Inc. (IMLFF)

Postby QualityStocks » Wed Aug 23, 2017 4:07 pm

No Eclipse in Sight for InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) as it Moves toward Clinical Trials

- Proprietary biosynthesis process to produce cannabinoids
- Cannabinoid bioinformatics system that identifies optimal R&D pathways
- Lead candidate targeting billion dollar market

Despite the awe-inspiring shadow cast by the moon on August 21, 2017, there’s no eclipse in sight for InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF). The Vancouver, Canada-based company continues its research and development (R&D) into the therapeutic benefits of cannabinoids, an activity that holds the promise of exceedingly rich reward. Peer valuations have skyrocketed, increasing the likelihood that unicorns may soon appear on the cannabis biotech landscape. With a triad of valuable core assets, it won’t be surprising if, sometime in the future, InMed turns out to be one of them.

InMed Pharmaceuticals has more to offer than the typical drug discovery and development company. Its triple play comprises a proprietary technology based on biosynthesis, a bioinformatics system, and a robust drug development pipeline, any one of which may propel this innovative biotech to success. The company has developed a process to manufacture cannabinoids by applying cannabinoid DNA to Escherichia-coli (E. coli) bacteria. The E. coli DNA is then removed, leaving just the cannabinoid DNA, which can then replicate in a process known as biosynthesis. Biosynthesis is widely employed in the pharmaceutical industry and is used, for example, to manufacture the insulin upon which millions of diabetics rely.

InMed’s bioinformatics system, employing proprietary algorithms, identifies the cannabinoids most likely to have beneficial therapeutic effect in serious diseases with high unmet medical needs. The program integrates data from numerous bioinformatics databases, including a database on the structure of currently approved pharmaceutical products and an extensive proprietary database of over 90 individual cannabinoid drugs found in cannabis. This bioinformatics tool has already identified several therapies, including the company’s two lead pipeline candidates, INM-750 and INM-085.

INM-750 is for the treatment of a rare genetic connective tissue disorder called epidermolysis bullosa (EB). EB is an orphan pediatric disease characterized by extremely fragile skin that affects roughly one out of every 20,000 births in the United States. The condition, which currently has no approved treatment or cure, has been called “The Worst Disease You’ve Never Heard Of” by the Dystrophic Epidermolysis Bullosa Research Association of America. INM-750 works by replacing missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB. It has potential global market revenues of approximately $1 billion.

INM-085 targets glaucoma, a leading cause of blindness, according to the Glaucoma Research Foundation. The drug reduces the elevated intra-ocular pressure that is often associated with glaucoma and so holds the promise of providing relief to the more than three million Americans who currently have glaucoma.

Both INM-750 and INM-085 are in the pre-clinical phase, and InMed is taking the lead with the former, which it is hoping to advance to phase I clinical trials in 2018. If all goes well, INM-750 is expected to be in phase III by 2020, setting InMed on a trajectory, if peer comparisons are any indication, to a much higher valuation than its current one of under $50 million. Scioderm, for example, was acquired by Amicus two years ago for $847 million. This acquisition was based on the results of a phase II study of its sole clinical asset Zorblisa, which involved only 42 patients. Zorblisa, for the treatment of EB, is currently in phase III.

InMed’s pipeline is in good hands. Its chief scientific officer is Dr. Sazzad Hossein, who brings more than 20 years of academic and industrial experience in new drug discovery and natural health product development to the C-suite. He was, at one time, group leader and senior scientist at Biotechnology Research Institute of National Research Council Canada, the Government of Canada’s prime biotechnology research organization, where he set up a pharmacology laboratory to evaluate the safety and efficacy of new drugs under development in the areas of cancer and cardiovascular and ocular diseases. He is also the author of more than 40 peer-reviewed papers, primarily in the pharmacology, genetics and nutritional sciences.

InMed’s chief medical officer is Dr. Ado Muhammed. Muhammed joined the company from GW Pharmaceuticals, developer of Sativex, where he was associate medical director, distinguishing InMed as the only biopharmaceutical company in North America with a senior GW team member on its executive team.

For more information, visit the company’s website at www.InMedPharma.com
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 613
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: InMed Pharmaceuticals, Inc. (IMLFF)

Postby QualityStocks » Fri Sep 01, 2017 3:56 pm

NetworkNewsBreaks – InMed Pharmaceuticals (CSE: IN) (OTCQB: IMLFF) Could Prove to Be a Cannabis Biotech Unicorn

The recent solar eclipse that enthralled the world has come and gone, but no shadow of an eclipse is on the horizon to blot out the progress of InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF). As peer valuations have soared in Canada’s cannabis market, InMed continues its promising R&D efforts into the therapeutic benefits of marijuana, and this Vancouver, Canada-based company may just prove to be one of the unicorns of Canada’s cannabis biotech market. An excerpt from an article further discussing this reads: “InMed Pharmaceuticals has more to offer than the typical drug discovery and development company. Its triple play comprises a proprietary technology based on biosynthesis, a bioinformatics system, and a robust drug development pipeline, any one of which may propel this innovative biotech to success. The company has developed a process to manufacture cannabinoids by applying cannabinoid DNA to Escherichia-coli (E. coli) bacteria. The E. coli DNA is then removed, leaving just the cannabinoid DNA, which can then replicate in a process known as biosynthesis. Biosynthesis is widely employed in the pharmaceutical industry and is used, for example, to manufacture the insulin upon which millions of diabetics rely.”
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 613
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: InMed Pharmaceuticals, Inc. (IMLFF)

Postby QualityStocks » Tue Sep 12, 2017 3:42 pm

Cannabis Biotechs Taking Leading Stance in Global Marijuana Market

With leading recent estimates clocking the 2016 North American legal cannabis market between $6.7 and $7.2 billion, the only thing more impressive about the industry is the growth projections. Research estimates a whopping compound annual sales growth rate of 25 percent through 2021. This stupendous growth, driven by more and more states adopting medical and even recreational legislation, has combined with the fact that the FDA has not yet approved any drug product containing or derived from botanical marijuana to create a perfect storm for cannabis biotechs like Vancouver-based InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) (IMLFF Profile) and GW Pharmaceuticals (NASDAQ: GWPH). Medical marijuana has among the highest values in the broader marijuana space, and as with any burgeoning industry, savvy investors are looking for evidence of the market’s core value. A look at the operations of Canopy Growth Corp. (TSX: WEED) (OTC: TWMJF), Aphria, Inc. (TSX: APH) (OTC: APHQF) and Aurora Cannabis (TSX: ACB) (OTC: ACBFF) provides insight into various niches within the marijuana industry to help identify why cannabis biotechs are the value sweet spot.

Despite its incredible potential, the success of medicinal marijuana’s success in the U.S. is crimped by cultivation capabilities. Due to the notoriously stringent regulatory environment in the U.S., much of the research and even plant cultivation has historically been done outside the country, with Israel rapidly evolving into the premier cannabis research and development location on earth, as the nation’s scientists and producers chase what will potentially be a $50 billion global market by 2025. Second only to Israel in this regard is Canada, where top growers are benefitting from Access to Cannabis for Medical Purposes Regulations (ACMPR) that allow commercially licensed production. This limited participation market has been very good for Canadian growers that have achieved licensing, with only 58 participants to date. However, the real value of the industry lies in the biotechs using cannabinoids extracted from the cannabis plant to develop their drug candidates and potentially change the entire future landscape of the medical marijuana industry.

Evidence of the value of cannabis biotechs is revealed in the Bloomberg Intelligence Global Cannabis Competitive Peers Index (http://nnw.fm/8bZ6k), which shows the collective market cap of cannabis bio-pharma at $5.6 billion, outpacing the valuation of cannabis producers at $3.4 billion. While current cannabis drug development is handicapped by the expensive industry standard “grow-harvest-extract-purify” process, GW Pharmaceuticals’ ability to jump from $8 a share to more than $120 a share following news of its new drug, is a prime example of the types of gains cannabis biotechs can achieve, and what makes them dominate the Bloomberg index.

As noted in the Bloomberg piece, InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) could become a major breakout player, differentiating itself from leading developers like GW Pharmaceuticals with biosynthetic offerings and two key drug indications. This is a key advantage for InMed, which has a market cap of $34 million, but to better understand this advantage and valuation potential, it pays to examine the underlying market dynamics in greater detail.

There are more than 90 cannabinoids that have been isolated from cannabis, each affecting the body’s cannabinoid receptors and responsible for unique pharmacological effects. Because these cannabinoids are so small in size, isolating these compounds in usable volume requires the cultivation of large quantities of cannabis, currently some cannabinoid compounds are found in such small volumes in the plant they are not commercially viable for study in drug development.

InMed Pharmaceuticals, however, enjoys the unique benefit of developing a cannabinoid biosynthesis process to provide access to the entire suite of all 90 plus naturally-occurring cannabinoids (not just THC or cannabidiol). Rather than having to rely on outside cultivators in Israel or Canada, InMed uses its proprietary, high-yield biosynthesis process capable of manufacturing pharmaceutical grade, bio-identical cannabinoids in the lab.

Diseases such as the primary targets of InMed’s current drug development pipeline, like glaucoma, which the company is targeting the root cause of via INM-085. Designed as a topical formulation which facilitates absorption by the eye, the proprietary, polymer-based INM-085 is a novel, multi-target, multi-mechanism package of cannabinoids focused on relieving the intra-ocular pressure build up which leads to optic nerve damage in glaucoma patients. INM-085 simultaneously provides key neuroprotectant properties that help optic nerve tissues and retinal ganglion cells survive adverse conditions. Glaucoma therapeutics was a $5.7 billion market only two years ago, with projections of a 3.4 percent CAGR through 2024, and the broader ophthalmic drug market is on-track to top $30 billion by 2020.

Another disease currently targeted by InMed’s development pipeline is epidermolysis bullosa (EB), a connective tissue disorder characterized by the absence of certain proteins in the skin, and currently classed as an orphan disease for which there remains significant unmet medical need. INM-750 is just as novel as INM-085, utilizing a broad-spectrum approach to modulate levels of the key protein responsible for protecting epithelial (skin) cells from damage and stress, known as keratin. In addition, INM-750 was specifically designed to alleviate associated symptoms like inflammation, itching, pain, while promoting wound healing, and skin cell regeneration. INM-750 is on target for clinical trials as early as next year and the global market for EB and glaucoma combined is easily over $6 billion.

These target markets are just the tip of the iceberg, in terms of market opportunity. With a valuation of $3.4 billion, GW Pharmaceuticals (NASDAQ: GWPH) may be the frontrunner in the search for cannabis-based therapeutics, but small biotechs like InMed (CSE: IN.c) (OTC: IMLFF) are demonstrating the vast potential of cannabis therapies and their value in the broader medical industry.

GW Pharmaceuticals has been in the cannabinoid research game since the late 90s and has become one of the most talked about developers of plant-derived cannabinoid therapeutics today. Widely known for bringing the world’s first plant-derived cannabinoid prescription drug (Sativex) to market for spasticity in multiple sclerosis patients, GW Pharmaceuticals markets the drug in 29 countries outside the U.S. and is currently in phase 3 pivotal trials for Epidolex, which has been granted both Orphan Drug Designation and Fast Track Designation by the FDA. The company also famously decided to keep its entire plant production footprint in the UK last year, despite driving hard toward sizeable U.S. markets with Epidolex, and migrating its shares from London markets exclusively to the Nasdaq exchange.

The success and valuation of Canada’s medical marijuana growers, cultivators and producers sheds light on increasing global demand and necessity for high-volume, high-quality plants for medicinal purposes.

Canopy Growth’s (TSX: WEED) (OTC: TWMJF) is among leaders on the production side of the marijuana industry, with a market cap of $1.4 billion (CAD) as of September 11. The company’s Bedrocan brand is billed as the epitome of medical-grade cannabis due to decades of selection and refinement. Enabling the company to produce consistent, standardized whole bud cannabis strains, as well as see those strains become used extensively by clinical researchers across seven European countries. With a production footprint of over half a million square feet, Canopy Growth is one of the biggest growers in Canada. The company recently moved to further solidify its expansion in New Brunswick with the acquisition of ACMPR applicant Spot Therapeutics, which when licensed will produce roughly 8,800 pounds a year, and when fully expanded will provide around 100,000 square feet of production space. The company also expanded its Smiths Falls and our Bowmanville South footprints last quarter by 33% and 200% respectively.

Currently valued at $831.5 million (CAD), Aphria, Inc. (TSX: APH) (OTC: APHQF) is one of the lowest cost producers in Canada and was the first publicly licensed producer to go cash flow positive from operations. The recent announcement of a $25 million investment in order to effectively gain a strategic U.S. presence via one of only seven licensees in the entire state of Florida is a big move for the company, which will operate in the U.S. under the Aphria USA brand. A big move, but with nearly 21 million people in Florida and many of them elderly, this market could be a real goldmine for Aphria, as it represents some 14 percent of the total U.S. medical cannabis market, valued at over $1.1 billion.

Aurora Cannabis, Inc. (TSX: ACB) (OTC: ACBFF) surpassed 19,000 active registered patients in the company’s first 20 months after initial product sales and has over 55,000 square feet in Alberta at its state-of-the-art production facility. Aurora is also currently in the process of tacking on an additional 840,000 square feet across two other sites in Canada. The company owns a 19.9% stake in the first Australian company licensed to cultivate and conduct research on medical cannabis, Cann Group Limited. As well as owning a leading Germany-based wholesale importer, exporter, and distributor of medical cannabis, known as Pedanios. Pedanios even recently passed the first stage of the tender application process in Germany to become a licensed medical cannabis producer, which will further expand the company’s presence in the EU. Aurora’s market cap is $969.0 million (CAD)

As investors find their footing in the global marijuana industry, the potential for cannabis biotechs is reaching unprecedented proportions thanks to the innovations and drug development capabilities of companies like InMed and behemoths like GW Pharmaceuticals.

For more on IMLFF please visit: InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF)
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 613
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: InMed Pharmaceuticals, Inc. (IMLFF)

Postby QualityStocks » Tue Sep 12, 2017 4:20 pm

NetworkNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Files Provisional Patent Covering Proprietary Biosynthesis Program

Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced its filing of a provisional patent application pertaining to the company’s biosynthesis program for the manufacture of cannabinoids that are identical to those found in nature. Per the news release, this patent application, once converted into an international Patent Cooperation Treaty (PCT) application and pursued in key jurisdictions around the world, will offer significant commercial protections for InMed’s promising E. coli-based expression system, which enables the manufacture of any of the 90+ cannabinoid compounds found in the cannabis plant. “This novel approach to the biosynthesis of cannabinoids is a game-changer for drug development,” Dr. Vikramaditya Yadav, Assistant Professor of Chemical and Biological Engineering at the University of British Columbia, stated in the news release. “The importance of producing cannabinoids that are identical to the naturally occurring compounds cannot be overstated. Many drug development efforts with synthetic derivatives have failed.”
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 613
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: InMed Pharmaceuticals, Inc. (IMLFF)

Postby QualityStocks » Wed Sep 13, 2017 4:05 pm

Biosynthesis Technology Could Transform Cannabinoid Production

NetworkNewsWire Editorial Coverage: The upward trajectory of the cannabis industry has garnered comparisons to the Internet boom of the early 2000s, as North American sales are on pace to record a compound annual growth rate of 25 percent through 2021, according to Arcview Market Research (1). These comparisons are certainly attention-grabbing, but the full potential of the evolving marijuana market could be even larger. InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) (IMLFF Profile), a Vancouver-based biopharmaceutical company, has developed a robust, high-yield biosynthesis process capable of enabling the manufacture of all 90+ naturally-occurring cannabinoids found in the cannabis plant. This could be a game changing development for companies operating within the burgeoning sector, including Axim Biotechnologies, Inc. (OTCQB: AXIM), GW Pharmaceuticals (NASDAQ: GWPH), Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) and pharmaceutical heavyweight Eli Lilly and Company (NYSE: LLY).

Perhaps the clearest way to demonstrate the potential of an effective cannabinoid biosynthesis platform is to study a more established product – bio-synthetic insulin. Healthline estimates that 29.1 million people in the United States have diabetes, with diagnosed cases costing the country an estimated $245 billion in 2012. Although the chronic disease accounted for nearly 1.6 million deaths in 2015, according to data from the World Health Organization, a scientific breakthrough in 1921 greatly improved the survivability of diabetes. As documented by a contributor to The Seed Investor, it was then that a team of Canadian researchers discovered a way to process pig pancreases into a human insulin replacement.

While this discovery certainly improved the outlook for diabetes sufferers, it was just the first step toward the insulin market as it exists today. Originally, pharmaceutical insulin was produced directly from the organs of pigs, with it taking roughly “5,000 pig pancreases to produce just eight ounces of insulin.” Put simply, this process was expensive and time-consuming, and, while producer Eli Lilly and Company certainly capitalized on the breakthrough, a discovery in the 1970s once again changed the game. A small biotechnology firm called Genentech used recombinant DNA techniques to successfully produce a bio-synthetic “human” insulin, making it the first human protein to be manufactured through biotechnology. In addition to being significantly cheaper to produce than animal-derived alternatives, this synthetic insulin was shown to cause less allergic reactions in patients. Within a few years, biosynthetic insulin replaced the vast majority of animal-based alternatives, and the companies at the heart of the innovation have reaped the rewards. Genentech was acquired by Roche Holdings for $48 billion in 2009, while a 2014 report from Transparency Market Research predicted that the global insulin market will reach $32.24 billion by 2019.

Parallels between the insulin market of the 1960s and today’s pharmaceutical cannabinoid industry are too clear to be ignored. Cannabis biotech companies are currently producing millions of plants each year in order to extract the cannabinoids that are central to their products and development candidates. However, maintaining the controlled conditions required to produce consistent plants is both costly and time-consuming, and competitive market conditions in drug development cost will see these pressures from growing and manufacturing expenses. Agricultural and Capital Expense cost are high, from Land, facility costs with high-efficiency lighting systems and sophisticated greenhouse production facilities, investors are pouring millions of dollars into pot production. The cost for the cannabinoids, the active pharmaceutical ingredients (API’s) needed in cannabis drug development are staggeringly high. InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), with its innovative biosynthesis technology utilizing modified E-coli bacteria, could be approaching the introduction of a cheaper and better alternative for providing the API’s in the massive industry’s cannabinoid-focused segment following its filing of a provisional patent application pertaining to the technology earlier this week.

Potential benefits of biosynthesis of cannabinoids are wide-ranging, as InMed Pharmaceuticals notes in its corporate presentation. The cost savings versus traditional growing and extraction methods are certainly noteworthy (and they echo the benefits of bio-synthetic insulin nicely), but monetary benefits are just the tip of the iceberg. Because the cannabinoids produced using InMed’s proprietary manufacturing techniques are bioequivalent to the naturally-occurring compounds, biosynthesis could enable enhanced quality control and purification. Importantly, the technology could be key in unlocking the minor cannabinoids that are currently economically unfeasible to produce and comprehensively study. The company estimates that its cannabinoid biosynthesis process, a method that’s been likened to a “pharmaceutical copy machine” for its ability to produce bioequivalent compounds.

“This novel approach to the biosynthesis of cannabinoids is a game-changer for drug development. The importance of producing cannabinoids that are identical to the naturally occurring compounds cannot be overstated. Many drug development efforts with synthetic derivatives have failed,” Dr. Vikramaditya Yadav, Assistant Professor of Chemical and Biological Engineering at University of British Columbia, a co-inventor of the biosynthesis technology, stated in a recent news release (http://nnw.fm/Z30dH). “In our extensive experimentation, the E. coli system is more robust and more efficient for the manufacturing of cannabinoids as compared to other microbial platforms.”

Links between Eli Lilly’s early ventures in the synthetic insulin market and InMed’s current forays into cannabinoid biosynthesis were reaffirmed by InMed’s January 2017 appointment of Martin Bott to its board of directors. Following Bott’s appointment, market analysis firm CFN Media called the move “a strong vote of confidence for [InMed’s] future.” Bott has worked at Eli Lilly for nearly 30 years prior to his appointment to the InMed board, overseeing the drug giant’s investment of more than $1 billion into biosynthesis research. As InMed President and CEO Eric A. Adams noted in a news release following the addition, “Martin Bott has established a significant leadership position in financial and business expertise with one of the world’s leading pharmaceutical companies. His depth of knowledge in navigating the complexities in healthcare finance and operations on a global level will be invaluable to InMed.”

InMed’s intellectual property portfolio also includes a promising drug development pipeline targeting unmet medical conditions using non-THC cannabinoids. The company’s lead candidate, INM-750, is currently being evaluated as a topical treatment for epidermolysis bullosa, an orphan pediatric disease, characterized by extremely fragile skin, that has no currently approved therapies. InMed estimates the market potential of INM-750 at $1 billion, with phase I clinical trials scheduled to begin in 2018. The company is also developing INM-085 for the treatment of glaucoma, a serious eye disease with a global market valued in excess of $5 billion. INM-085 is currently being evaluated in pre-clinical studies. These drug candidates further strengthen InMed’s position within the burgeoning cannabis sector, providing an additional application for its groundbreaking biosynthesis platform.

The activity of other cannabis industry players highlights the huge market potential of InMed’s novel approach to cannabinoid biosynthesis. Axim Biotechnologies, Inc. (AXIM) is currently developing a diversified and robust clinical pipeline of cannabinoid-based products. Its most advanced program is its phase II clinical trial of its MedChewRx™ chewing gum for the treatment of irritable bowel syndrome. Axim anticipates completing this trial in the near-term and advancing toward a pivotal phase III clinical trial by early next year.

Coinciding with this advancement, Axim has made numerous moves in recent months to secure the needed supply of cannabinoids required to evaluate the efficacy of its development pipeline. In addition to importing pharmaceutical-grade hemp oil from Italy, Spain and Denmark, Axim recently purchased land in the Netherlands in order to facilitate the construction of a state-of-the-art manufacturing facility. Per the company’s website, “Axim is in the process of developing a unique extraction and freeze-drying technology for production of molecularly/genetically controlled—therefore extremely pure—pharma-grade cannabinoids extracted from industrial hemp.” As noted in a November 2016 news release, this platform will focus primarily on the extraction of THC, the most commonly known cannabinoid derived from the cannabis plant.

GW Pharmaceuticals (GWPH) is well-known within the cannabis industry as the company behind the world’s first prescription drug derived from the cannabis plant, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 28 countries worldwide. The company’s lead cannabinoid product candidate is Epidiolex®, a liquid formulation of pure plant-derived cannabidiol being developed for the treatment of a number of rare childhood-onset epilepsy disorders. As noted on its website, GW is currently in a “unique position to develop and manufacture plant-derived cannabinoid formulations worldwide at sufficient quality, uniformity and scale,” but some analysts have expressed doubt regarding the sustainability of this model. In an article published last year by Seeking Alpha, a contributor noted the recent fall in CBD prices concurrent with increasing supply. “The popularity and history of cannabis growing, combined with the large amounts of arable land, cheap pharmaceutical manufacturing, and cheap labor in India should scare anyone invested in hemp farming,” the article states. “The price-points we are seeing now don’t seem sustainable.” Synthetic cannabinoids, as produced through InMed’s proprietary biosynthesis platform, could provide a long-term solution to this issue.

The recent activity of Zynerba Pharmaceuticals, Inc. (ZYNE) reiterates the potential marketability of InMed’s platform. Zynerba’s shares plummeted to 52-week lows last month after the company announced disappointing top-line results from its phase II study of ZYN002, marketed as the first and only synthetic CBD formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. As noted on its website, Zynerba’s product candidates are “synthetically manufactured per FDA/CGMP regulations” in an effort to “provide consistent potency and eliminate impurities in the product.” Similar to InMed’s biosynthesis platform, Zynerba’s manufacturing techniques offer several advantages over botanically-derived cannabinoids, dodging “the natural resources and security measures required to grow Cannabis, as well as the strict batch controls required by regulatory agencies in pharmaceutical manufacturing.”

A report published by the National Institutes of Health affirms that cannabinoids have a very high therapeutic index with low toxicity, and the market is currently filled with companies looking to translate these benefits into returns for shareholders. Since the 1980s, when Eli Lilly and Company (LLY) developed a synthetic THC product called Nabilone to treat nausea associated with chemotherapy, demand for biosynthetically-produced cannabinoids that are bioequivalent to those that occur naturally within the cannabis plant has been on the rise. InMed Pharmaceuticals could be approaching this breakthrough with its robust, high-yield biosynthesis process, presenting an enticing opportunity for investors looking to capitalize on rising demand for cannabinoid-based pharmaceuticals.

Editorial Sources:
1) Arcview Research http://nnw.fm/OHz8c

For more information on InMed Pharmaceuticals, Inc. please visit: InMed Pharmaceuticals
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 613
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: InMed Pharmaceuticals, Inc. (IMLFF)

Postby QualityStocks » Thu Sep 14, 2017 5:06 pm

InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Builds Moat around Proprietary Biosynthesis Technology

- Proprietary biosynthesis process to produce cannabinoids
- Provisional patent application filed
- Cost-effective methodology to produce trace cannabinoids

If you have any doubt that InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) is on the right track as it moves to protect its biosynthesis technology for cannabinoids, then a word from a famed figure may make you change your mind. Known worldwide for his investing prowess, Warren Buffett has said, “I don’t want a business that’s easy for competitors. I want a business with a moat around it with a very valuable castle in the middle” (http://nnw.fm/ILqd2). Naturally, the Sage of Omaha was referring to an economic moat and not its tangible water-filled counterpart. One obvious way of constructing such an economic moat would be by registering a patent, which is exactly what InMed is planning to do. The company, which specializes in the research and development (R&D) of novel, cannabinoid-based drug therapies, has announced the filing of a provisional patent application for its proprietary biosynthesis process for the manufacture of cannabinoids that are identical to those found in nature (http://nnw.fm/lGxK8).

This filing is the first step in setting up defenses. Under U.S. patent law, a provisional patent application filed with the United States Patent and Trademark Office (USPTO) allows the filer to get a filing date and book a place in the queue. But, just as importantly, it affords protection for up to 12 months without filing a complete patent application. The provisional application may later be converted into a non-provisional one or be replaced by a regular patent application. The process in Canada, although not the same, is very similar.

To obtain protection outside North America, the Patent Cooperation Treaty (PCT) offers one streamlined route. The PCT procedure facilitates a patent application in all contracting states that are signatories with one filing, obviously a boon, since 145 sovereign states are members of the PCT. The PCT process allows the filing of an “international patent application,” which acts as an initial application for a patent in any member country. However, an “international patent application” never matures into an “international patent”. No such animal exists. A PCT filing simply reduces the burden of individual filings to contracting states and acts as a patent application to the contracting state in which the patent is meant to go into effect. Patents are issued by sovereign states and are always limited to national boundaries.

InMed’s provisional patent application will protect the biosynthesis process it has developed for the production of cannabinoids. In itself, biosynthetic production of chemicals is nothing new, but it really took off in 1978 after Genentech succeeded in modifying Escherichia-coli (E-coli) bacteria to produce synthetic insulin, a breakthrough credited with saving thousands of lives. Insulin is required by diabetics, whose bodies either do not produce the hormone or handle it inefficiently, in order to absorb glucose. In its absence, blood sugar increases to levels that may damage internal organs. Before biosynthesis, insulin was produced from the pancreas of pigs and cows in a costly, rather inhumane process.

InMed’s biosynthesis technology involves a process that can be applied to manufacture all the naturally occurring cannabinoids, through which the DNA of the cannabinoid to be produced is applied to Escherichia-coli (E-coli) bacteria. The E-coli DNA is then removed, leaving just the cannabinoid DNA, which can then replicate and multiply. This process combines the inherent safety and known efficacy of the natural drug structures with the convenience, control and quality of a laboratory-based manufacturing process.

InMed’s biosynthesis methodology will likely be used to produce the less naturally occurring phytocannabinoids such as delta-8 tetrahydrocannabinol (Δ8 THC), cannabidivarin (CBDv), and tetrahydrocannabivarin (THCv), although, for the present, the company is not saying. Regardless of which cannabinoid castles InMed decides to build, they will all be protected by a sturdy economic moat.

For more information, visit the company’s website at www.InMedPharma.com
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 613
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: InMed Pharmaceuticals, Inc. (IMLFF)

Postby QualityStocks » Tue Sep 19, 2017 4:17 pm

NetworkNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Retains Consulting Services of Ben Paterson

Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced that it has retained the consulting services of Ben Paterson, P.E., to assist in defining the pathway for scale-up, purification and manufacturing strategies related to the company’s cannabinoid biosynthesis program. Paterson brings nearly four decades of experience in developing pharmaceutical manufacturing and purification processes to the InMed team, having previously served as a senior engineering advisor with Pharmaceutical giant Eli Lilly and Company for nearly four decades. “Mr. Paterson brings significant experience in all facets of biosynthesis manufacturing and facility design,” Eric A. Adams, president and CEO of InMed, stated in the news release. “His expertise directing complex capital projects, overseeing facilities and equipment, and interfacing with various stakeholders will be a significant asset to InMed.”
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 613
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: InMed Pharmaceuticals, Inc. (IMLFF)

Postby QualityStocks » Thu Sep 21, 2017 6:33 pm

NetworkNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Announces Inclusion in CSE25 Index

Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced that it has been included in the CSE25 Index after qualifying as one of the 25 largest companies in the CSE Composite Index. Per the update, the CSE25 Index is a subgroup of the CSE Composite Index, which was launched in 2015 and currently includes nearly half of the exchange’s listed companies and over 75 percent of the trading activity on the Canadian Securities Exchange. The CSE25 Index includes the top 25 securities contained within the CSE Composite Index based on market capitalization. According to the exchange, CSE25 companies account for more than 50 percent of the weighting of the larger CSE Composite Index, meaning that the 25 included stocks typically attract “considerable trading volume.”
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 613
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Previous

Return to QualityStocks Featured Companies

Who is online

Users browsing this forum: No registered users and 3 guests

cron